CoChat
Sign Up
Cited by 152Lung Cancer Treatments and MutationsChemotherapy-related skin toxicityHER2/EGFR in Cancer Research

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

Open access
Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J. +5 more·2015·Drugs
DOI 10.1007/s40265-015-0434-6PMC PMC4532717
Open this paper in CoChat — free accountOpen PDF

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying progression and improvement of quality of life over palliative platinum-based chemotherapy. The most common adverse events (AEs) are gastrointestinal (GI) (diarrhoea and stomatitis/mucositis) and cutaneous (rash, dry skin and paronychia). These are usually mild, but if they become moderate or severe, they can have a negative impact on the patient's quality of life (QOL) and lead to dose modifications or drug discontinuation. Appropriate management of AEs, including prophylactic measures, supportive medications, treatment delays and dose reductions, is essential. A consensus meeting of a UK-based multidisciplinary panel composed of medical and clinical oncologists with a special interest in lung cancer, dermatologists, gastroenterologists, lung cancer nurse specialists and oncology pharmacists was held to develop guidelines on prevention and management of cutaneous (rash, dry skin and paronychia) and GI (diarrhoea, stomatitis and mucositis) AEs associated with the administration of EGFR-TKIs. These guidelines detail supportive measures, treatment delays and dose reductions for EGFR-TKIs. Although the focus of the guidelines is to support healthcare professionals in UK clinical practice, it is anticipated that the management strategies proposed will also be applicable in non-UK settings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-015-0434-6

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. [1]Siegel R Ma J Zou Z Jemal A Cancer statistics, 2014 CA. 2014 64 1 9 29 24399786
  2. [2]Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol. 2012;23(Suppl 7):vii56–64. 22997455
  3. [3]Lynch TJ Bell DW Sordella R Gurubhagavatula S Okimoto RA Brannigan BW Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med. 2004 350 21 2129 2139 10.1056/NEJMoa040938 15118073 · DOI · Paper page
  4. [4]Pao W Miller V Zakowski M Doherty J Politi K Sarkaria I EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci 2004 101 36 13306 13311 10.1073/pnas.0405220101 15329413 PMC516528 · DOI · Paper page
  5. [7]Han JY Park K Kim SW Lee DH Kim HY Kim HT First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 2012 30 10 1122 1128 10.1200/JCO.2011.36.8456 22370314 · DOI · Paper page
  6. [8]Inoue A Kobayashi K Maemondo M Sugawara S Oizumi S Isobe H Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) Ann Oncol 2013 24 1 54 59 10.1093/annonc/mds214 22967997 · DOI · Paper page
  7. [9]Maemondo M Inoue A Kobayashi K Sugawara S Oizumi S Isobe H Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med. 2010 362 25 2380 2388 10.1056/NEJMoa0909530 20573926 · DOI · Paper page
  8. [11]Mitsudomi T Morita S Yatabe Y Negoro S Okamoto I Tsurutani J Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 2010 11 2 121 128 10.1016/S1470-2045(09)70364-X 20022809 · DOI · Paper page
  9. [12]Zhou C Wu YL Chen G Feng J Liu XQ Wang C Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 2011 12 8 735 742 10.1016/S1470-2045(11)70184-X 21783417 · DOI · Paper page
  10. [13]Rosell R Carcereny E Gervais R Vergnenegre A Massuti B Felip E Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 2012 13 3 239 246 10.1016/S1470-2045(11)70393-X 22285168 · DOI · Paper page
  11. [17]Keedy V Temin S Somerfield M Beasley M Johnson D McShane L American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non–small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy J Clin Oncol 2011 29 15 2121 2127 10.1200/JCO.2010.31.8923 21482992 · DOI
  12. [21]Arriola E Reguart N Artal A Cobo M Garcia-Campelo R Esteban E Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel Future Oncol 2015 11 2 267 277 10.2217/fon.14.214 25236437 · DOI
  13. [22]Harandi A Zaidi AS Stocker AM Laber DA Clinical efficacy and toxicity of anti-EGFR therapy in common cancers J Oncol. 2009 2009 567486 10.1155/2009/567486 19424511 PMC2677718 · DOI
  14. [23]Lacouture ME Mechanisms of cutaneous toxicities to EGFR inhibitors Nat Rev Cancer 2006 6 10 803 812 10.1038/nrc1970 16990857 · DOI
  15. [24]Thatcher N Nicolson M Groves RW Steele J Eaby B Dunlop J Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K Oncologist 2009 14 8 840 847 19679688
  16. [25]Lynch TJ Jr Kim ES Eaby B Garey J West DP Lacouture ME Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management Oncologist 2007 12 5 610 621 10.1634/theoncologist.12-5-610 17522250 · DOI
  17. [26]Hirsh V Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer Curr Oncol 2011 18 3 126 138 10.3747/co.v18i3.877 21655159 PMC3108866 · DOI
  18. [27]Lacouture M, Schadendorf D, Chu C-Y, Uttenreuther-Fischer M, O’Brien D, Hauschild A. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):1–8. 23506519
  19. [28]Potthoff K Hofheinz R Hassel JC Volkenandt M Lordick F Hartmann JT Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion Ann Oncol 2011 22 3 524 535 10.1093/annonc/mdq387 20709812 · DOI
  20. [31]Rockwell PG Acute and chronic paronychia Am Fam Physician 2001 63 6 1113 1116 11277548
  21. [32]Yang JC Reguart N Barinoff J Kohler J Uttenreuther-Fischer M Stammberger U Diarrhea associated with afatinib: an oral ErbB family blocker Expert Rev Anticancer Ther 2013 13 6 729 736 10.1586/era.13.31 23506556 · DOI
  22. [33]Nightingale JM The medical management of intestinal failure: methods to reduce the severity Proc Nutr Soc. 2003 62 3 703 710 10.1079/PNS2003283 14692605 · DOI
  23. [34]Bensinger W Schubert M Ang K Brizel D Brown E Eilers J NCCN Task Force Report: prevention and management of mucositis in cancer care J Natl Compr Canc Netw 2008 6 Suppl 1 S1 S21 18289497
  24. [37]Papas AS Clark RE Martuscelli G O’Loughlin KT Johansen E Miller KB A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation Bone Marrow Transplant 2003 31 8 705 712 10.1038/sj.bmt.1703870 12692611 · DOI
  25. [38]Tombes M Gallucci B The effects of hydrogen peroxide rinses on the normal oral mucosa Nurs Res. 1993 42 6 332 337 10.1097/00006199-199311000-00003 8247815 · DOI
  26. [39]Elting LS Cooksley C Chambers M Cantor SB Manzullo E Rubenstein EB The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis Cancer 2003 98 7 1531 1539 10.1002/cncr.11671 14508842 · DOI
  27. [40]Turhal NS Erdal S Karacay S Efficacy of treatment to relieve mucositis-induced discomfort Support Care Cancer 2000 8 1 55 58 10650899
  28. [41]Choi S-E Kim H-S Sodium bicarbonate solution versus chlorhexidine mouthwash in oral care of acute leukemia patients undergoing induction chemotherapy: a randomized controlled trial Asian Nurs Res. 2012 6 2 60 66 10.1016/j.anr.2012.05.004 25030829 · DOI
  29. [42]Sonis S Regimen-related gastrointestinal toxicities in cancer patients Curr Opin Support Palliat Care 2010 4 1 26 30 10.1097/SPC.0b013e328335fb76 20040879 · DOI
  30. [43]Keefe DM Schubert MM Elting LS Sonis ST Epstein JB Raber-Durlacher JE Updated clinical practice guidelines for the prevention and treatment of mucositis Cancer 2007 109 5 820 831 10.1002/cncr.22484 17236223 · DOI
  31. [44]Lalla R Sonis S Peterson D Management of oral mucositis in patients who have cancer Dent Clin N Am 2008 52 1 61 77 10.1016/j.cden.2007.10.002 18154865 PMC2266835 · DOI
  32. [45]Manojlovic N Babic D Radiation-induced rectal ulcer–prognostic factors and medical treatment Hepato-gastroenterology. 2004 51 56 447 450 15086179
  33. [46]Hirsh V Encouraging data out of the 2010 Congress of the European Society for Medical Oncology with respect to non-small-cell lung cancer Curr Oncol. 2010 17 6 7 8 10.3747/co.v17i6.795 21151402 PMC2993445 · DOI

Cited by

Sorted by citations

Authors
Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., Thomas, A., Thatcher, N., & Nicolson, M.
Affiliations
  • Cancer Research UK (GB)
  • Guy's Hospital (GB)
  • Salford Royal NHS Foundation Trust (GB)
  • University of London (GB)
  • Velindre Cancer Centre (GB)
  • Hairmyres Hospital (GB)
  • St James's University Hospital (GB)
  • Royal Liverpool University Hospital (GB)
  • Russells Hall Hospital (GB)
  • Aberdeen Royal Infirmary (GB)
Corresponding author
Califano, R.
ORCID
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2015-07-18
Volume
75
Issue
12
Pages
1335-1348
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
DOI
10.1007/s40265-015-0434-6
PMC
PMC4532717
OpenAlex
W1896254854
Cited by
152
References
4
Citations by year
2026: 12 · 2025: 17 · 2024: 10 · 2023: 10 · 2022: 11 · 2021: 18 · 2020: 26 · 2019: 13 · 2018: 11 · 2017: 13 · 2016: 8 · 2015: 3
FWCI
9.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Drugs (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Cancer Research UK (13044)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
EGFR tyrosine kinase inhibitors, adverse event management, non-small cell lung cancer, gefitinib, erlotinib, afatinib, cutaneous adverse events, rash, dry skin, paronychia, gastrointestinal adverse effects, diarrhea, stomatitis, mucositis, dose reduction, supportive care, quality of life, expert consensus recommendations
MeSH terms
Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Dose-Response Relationship, Drug, Gastrointestinal Diseases, United Kingdom, Humans, Lung Neoplasms, Mutation, Quality of Life, Risk Factors, Skin Diseases, Signal Transduction, Treatment Outcome, Consensus, Protein Kinase Inhibitors, Molecular Targeted Therapy, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review